Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: Role of comorbidities and physicians' perceptions

HIV Medicine

Volumn 14, Issue 7, 2013, Pages 430-436

  Winnock, M ^a   Bani Sadr, F ^b   Pambrun, E ^a   Loko, M A ^a   Carrieri, P ^c   Neau, D ^d   Morlat, P ^a   Marchou, B ^e   Dabis, F ^a   Salmon, D ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d HÔPITAL PELLEGRIN   (France)

^e CHU PURPAN   (France)

Author keywords

HCV treatment adherence; HIV treatment adherence; HIV HCV coinfection

Indexed keywords

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; PRIORITY JOURNAL;

HCV TREATMENT ADHERENCE; HIV TREATMENT ADHERENCE; HIV/HCV COINFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; COINFECTION; COMORBIDITY; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; RIBAVIRIN; YOUNG ADULT;

EID: 84879840213     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12023     Document Type: Article

References (24)

1. Bani-Sadr F, Lapidus N, Bedossa P etal. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008; 46: 768-774.
2. Loko MA, Bani-Sadr F, Winnock M etal. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18: e307-e314.
3. Salmon-Ceron D, Rosenthal E, Lewden C etal. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol 2009; 50: 736-745.
4. Carrat F, Bani-Sadr F, Pol S etal. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848.
5. Torriani FJ, Rodriguez-Torres M, Rockstroh JK etal. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450.
6. Cacoub P, Halfon P, Rosenthal E etal. Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: modifications in three consecutive large surveys between 2004 and 2009. J Hepatol 2010; 53: 230-237.
7. Macias J, Berenguer J, Japon MA etal. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056-1063.
8. Angeli E, Mainini A, Meraviglia P etal. Eligibility and feasibility of the treatment of chronic hepatitis C in a Cohort of Italian HIV-positive patients at a single HIV reference center. AIDS Patient Care STDS 2011; 25: 295-301.
9. Reiberger T, Obermeier M, Payer BA etal. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011; 16: 815-824.
10. Rapport du Groupe. d'Experts 2008 sur la prise en charge médicale des patients infectées par le VIH, sous la direction du Pr Patrick Yeni 2008:254-285.
11. Loko MA, Salmon D, Carrieri P etal. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis 2010; 10: 303.
12. Castera L, Vergniol J, Foucher J etal. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
13. Fuhrer RRF. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French). Psychiatrie et Psychobiologie 1989; 4: 163-166.
14. Justice AC, Holmes W, Gifford AL etal. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001; 54 (Suppl 1): S77-S90.
15. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol 1995; 56: 423-432.
16. Rockstroh JK, Bhagani S, Benhamou Y etal. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-88.
17. McHutchison JG, Manns M, Patel K etal. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
18. Maggiolo F, Ravasio L, Ripamonti D etal. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40: 158-163.
19. Glass TR, Rotger M, Telenti A etal. Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. PLoS ONE 2012; 7: e29186.
20. Wagner G, Chan Osilla K, Garnett J etal. Patient characteristics associated with HCV treatment adherence, treatment completion, and sustained virologic response in HIV coinfected patients. AIDS Res Treat 2011; 2011: 903480.
21. Smith SR, Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, Fried MW. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007; 41: 1116-1123.
22. Starace F, Ammassari A, Trotta MP etal. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31 (Suppl 3): S136-S139.
23. Lazo M, Gange SJ, Wilson TE etal. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007; 45: 1377-1385.
24. Weiss JJ, Alcorn MC, Rabkin JG, Dieterich DT. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol 2012; 56: 503-504.